Navigation Links
Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
Date:7/30/2008

ents with heart failure. Results from Nile's Phase Ib and Phase IIa trials are expected to be available in 2008.

About CD-NP

CD-NP is a novel chimeric natriuretic peptide in clinical development for an initial indication of acute decompensated heart failure (ADHF). CD-NP was rationally designed by scientists at the Mayo Clinic's cardio-renal research labs. Current therapies for ADHF, including B-type natriuretic peptide, have been associated with favorable pharmacologic effects, but have also been associated with hypotension and decreased renal function which limit their utility in clinical practice. CD-NP was designed to preserve the favorable effects of current therapies while preventing or attenuating the hypotensive response, and enhancing or preserving renal function.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, fu
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... SEATTLE , BERKELEY, Kalifornien, und KOPENHAGEN, ... CMC Biologics, Inc. , ein Weltmarktführer der ... und anderen therapeutischen Proteinen, gab heute bekannt, ... Expansionsstrategie der Produktionskapazität den Ausbau der nordamerikanischen ... , mit der Ergänzung  einer Einweg-Anlage Bioreactor ...
(Date:6/30/2015)... June 30, 2015  EnteroMedics Inc. (NASDAQ: ETRM ... neuroblocking technology to treat obesity, metabolic diseases, and other ... public offering  of 40,229,886 units. Each unit consists of ... A warrant to purchase one share of common stock, ... one share of common stock, at a purchase price ...
(Date:6/30/2015)... 2015  Egalet Corporation (Nasdaq: EGLT ... company focused on developing, manufacturing and marketing ... from a Category 3 human abuse liability ... oral oxycodone product candidate in late-stage clinical ... enough to require daily, around-the-clock opioid treatment ...
Breaking Medicine Technology:CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... YONKERS, N.Y., Sept. 27, 2011 As a result ... that could be dangerous to their health, according to ... Americans who currently take a prescription medicine told pollsters ... a doctor,s visit or medical procedure, declining tests, or ...
... Pa., Sept. 27, 2011 Inovio Pharmaceuticals, Inc. (NYSE ... development of synthetic immunogens against cancers and infectious diseases, ... Research and Development Agreement (CRADA) with the United States ... Plum Island Animal Disease Center. This collaboration will evaluate ...
Cached Medicine Technology:Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 2Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 3Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 4Consumer Reports Poll: 48 Percent of Americans on Meds Making Risky Health Care Tradeoffs 5Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 2Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 3Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 4
(Date:6/30/2015)... ... June 30, 2015 , ... Dr. Sammy Masri of Masri Sports Medicine ... specializes in the diagnosis and treatment of non-surgical sports and other musculoskeletal injuries for ... in recreational athletics and use exercise to stay healthy and active. Dr. Masri seeks ...
(Date:6/30/2015)... ... June 30, 2015 , ... MJH Associates ... HRA Healthcare Research & Analytics , a consultative healthcare market research practice that ... of businesses. HRA offers quantitative and qualitative, custom and multi-client primary market research ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... are partnering to improve access to cancer prevention, screening and care for the ... have announced an affiliation that will see Roswell Park faculty providing clinical consultations ...
(Date:6/30/2015)... NY (PRWEB) , ... June 30, 2015 , ... New ... New York July 7th and 11th 2015. Timber frame post and beam raisings offer ... , “Raising a timber frame is an important and exciting event ...
(Date:6/30/2015)... ... June 30, 2015 , ... LifeAID Beverage Company has ... leading organizations dedicated to raising worldwide awareness of the burgeoning “adaptive” movement, I ... now the official charity of FitAID. I AM ADAPTIVE is a non-profit whose ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 4Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 5Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 2Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 3Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 4Health News:Intercontinental Oncology Partnership Brings Access to Specialized Cancer Care to Nigeria 5Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 2Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 3Health News:Join New Energy Works Timberframers in Raising the Frames in Western New York 4Health News:LifeAID Beverage Company Partners With The Adaptive Movement 2Health News:LifeAID Beverage Company Partners With The Adaptive Movement 3
... of a fatty acid known as docosahexaenoic acid (DHA) ... //of developing dementia and Alzheimer’s disease, according to a ... have all been found to increase the risk of ... 70 percent of cases of dementia in the elderly, ...
... A research article published in the Lancet has brought to ... for the Indian //community. With only 2.2percent of the Adult ... clearly shows that the Indian body constitution is responsible. ... population in India between the age groups of 30 and ...
... flu can trigger a potentially debilitating neurological disorder called ... although they do stress that these findings should not ... ,Lead author of the study by the Institute ... "It is very, very small," referring to the risk ...
... Prescription sleep aids may do little to improve the ... with obstructive sleep apnea (OSA). A new study published ... of the American College of Chest Physicians (ACCP), finds ... aids were no more likely to use their CPAP ...
... as weight-loss surgery, obesity surgery and gastric-bypass surgery. In- ... problems. The mortality rate as per records is 2 ... ratings company, conducted a study on bariatric surgery complication ... differ in hospitals in accordance with their ratings. ...
... heat and humidity that lead to dehydration can signal a ... week at the American// College of Rheumatology Annual Scientific Meeting ... monosodium uric crystals, causes severe pain and swelling of the ... period of a few days, most often the big toe, ...
Cached Medicine News:Health News:Higher Level of Certain Fatty Acid Associated with Lower Dementia Risk 2Health News:Rare Neurological Disorder Linked to Flu shot 2Health News:Research Questions Use of Sleep Meds for Patients with Apnea 2Health News:Complications Resulting From Bariatric Surgery Vary With HealthGrades Ratings 2Health News:Complications Resulting From Bariatric Surgery Vary With HealthGrades Ratings 3Health News:It's the Heat and the Humidity: How Each Worsens Gout Symptoms 2
... Integra II SP MRI-Compatible Anesthesia System is perfect ... more than one type of anesthetic agent. ... and due to its wider stance, has a ... ventilator bellows assembly is utilized in both the ...
... Market leader in soft tissue repair in ... has developed the latest evolution in orthopedic ... ORTHOCORD Suture is as strong as any ... importantly, ORTHOCORD Suture handles like ETHIBOND®., ,ORTHOCORD ...
... PURPLE NITRILE* product family offers a comprehensive ... gloves were designed as an alternative for ... hypersensitivity to natural rubber latex proteins. The ... from latex and other synthetic gloves. Custom ...
... and the distinctive COLOR PURPLE* distinguish ... them for sterile clinical procedures when ... required. Theyre designed as an alternative ... Type 1 hypersensitivity to natural rubber ...
Medicine Products: